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Summary
 
This study investigated the role of natural killer (NK) cells as effectors of an immune response
 
against autologous cells modified by gene therapy. T lymphocytes were transduced with
LXSN, a retroviral vector adopted for human gene therapy that carries the selectable marker
 
gene 
 
neo
 
, and the autologous NK response was evaluated. We found that (i) infection with
LXSN makes cells susceptible to autologous NK cell–mediated lysis; (ii) expression of the 
 
neo
 
gene is responsible for conferring susceptibility to lysis; (iii) lysis of 
 
neo
 
-expressing cells is
clonally distributed and mediated only by NK clones that exhibit human histocompatibility
leukocyte antigen (HLA)-Bw4 specificity and bear KIR3DL1, a Bw4-specific NK inhibitory
 
receptor; and (iv) the targets are cells from HLA-Bw4
 
1
 
 individuals. Finally, neo peptides an-
choring to the Bw4 allele HLA-B27 interfered with KIR3DL1-mediated recognition of HLA-
B27, i.e., they triggered NK lysis. Moreover, 
 
neo
 
 gene mutations preventing translation of two
of the four potentially nonprotective peptides reduced KIR3DL1
 
1
 
 NK clone–mediated auto-
logous lysis. Thus, individuals expressing Bw4 alleles possess an NK repertoire with the poten-
tial to eliminate autologous cells modified by gene therapy. By demonstrating that NK cells can
selectively detect the expression of heterologous genes, these observations provide a general
model of the NK cell–mediated control of viral infections.
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K cells express receptors that, upon interaction with
their MHC class I ligands, produce a signal inhibiting
killing of the autologous cell (reviewed in references 1 and
 
2). One type of receptor is a lectin-like heterodimer, CD94-
NKG2A, that recognizes the nonclassical MHC class Ib mol-
ecule HLA-E (3). The other is a family of Ig-like receptors
 
designated killer cell inhibitory receptors (KIRs)
 
1
 
 (4–6).
KIRs with two Ig domains (KIR2D) identify HLA-C allo-
 
types: KIR2DL1 (formerly designated p58.2) recognizes
group 2 HLA-C allotypes, whereas KIR2DL2 (p58.1) rec-
ognizes group 1 HLA-C allotypes. A KIR with three Ig
domains, KIR3DL1 (p70/NKB1), is specific for HLA-B
alleles sharing the Bw4 supertypic specificity. Therefore,
the diversity of human MHC class I allotypes collapses to
only three well-defined KIR supertypic ligands: group 1
HLA-C, group 2 HLA-C, and HLA-Bw4. In addition, a
homodimer of molecules with three Ig domains, KIR3DL2
(p70/140), has been shown to be specific for HLA-A3 and
-A11 (7). Thus, NK cells are activated in response to the
missing expression of self-class I molecules on target cells,
such as some allogeneic cells or tumor or virus-infected
cells. KIRs also distinguish peptides bound to MHC class I
molecules. NK cell recognition of class I alleles on target
cells is prevented, and, consequently, NK lysis is triggered by
amino acid substitutions along protective peptides loaded
onto empty class I molecules at the surfaces of transporter
for antigen presentation (TAP)-deficient cells (8–12). Ex-
ogenously loaded viral peptides also abrogate NK cell rec-
ognition of MHC ligands (13). Consequently, the NK cell
killing of virus-infected cells (14) may be triggered by re-
placement of self-peptides with endogenously synthesized
viral peptides.
Human gene therapy uses replication-deficient, recom-
binant viral vectors (reviewed in references 15 and 16). Lack
of sustained exogenous gene expression may be due to sev-
eral mechanisms, including specific immune reactions to
the genetically modified cells. Infection of immunocompe-
 
1
 
Abbreviations used in this paper:
 
 KIRs, killer cell inhibitory receptors; RT,
reverse transcriptase; TAP, transporter for antigen presentation. 
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tent mice with replication-defective adenoviruses elicits
a CD8
 
1
 
 CTL response that eliminates virus-infected cells
(17–22). In humans reinfused with retrovirally infected
cells, specific CTL immunity against the transgene product
has been implicated in sharp reductions in survival of autolo-
gous transduced cells (23, 24). Therefore, immunogenicity
of genetically modified cells may elicit specific immunity in
the host and limit the stability of gene expression in vivo.
In this study, we explored the role of NK cells in the
immune response to genetically modified autologous cells
and used the LXSN retroviral vector because it, or other
similar vectors, is currently adopted for human gene ther-
apy protocols (24–27). These vectors are potential targets
for immune recognition, as they express 
 
neo
 
, a heterolo-
gous antibiotic (G418)-resistance gene used for selection of
transfected packaging cell lines and gene marking studies in
vivo (28).
We found that (i) infection with the LXSN retroviral vec-
tor makes human cells susceptible to autologous NK cell–
mediated lysis, (ii) expression of the 
 
neo
 
 gene is responsible
for conferring susceptibility to lysis, (iii) the effectors are NK
cells that bear KIR3DL1 and exhibit HLA-Bw4 specificity,
and (iv) the targets are cells from HLA-Bw4
 
1
 
 individuals.
Finally, we found that neo protein peptides anchor to Bw4
alleles (such as B27) and interfere with KIR3DL1-mediated
recognition of Bw4 alleles, i.e., they trigger NK lysis. More-
over, 
 
neo
 
 gene mutations preventing translation of two of the
four potentially nonprotective peptides reduced KIR3DL1
 
1
 
NK clone–mediated autologous lysis.
 
Materials and Methods
 
Immunofluorescence and Flow Cytometry.
 
Indirect immunofluores-
cence with primary mAb plus secondary fluorochrome-conjugated
goat anti–mouse Ig antibodies (Southern Biotechnology Associ-
ates) and flow cytometry (FACSCalibur™; Becton Dickinson)
determined NK cell phenotypes. NK cell clones were identified
using an anti-CD16 mAb (Immunotech). Expression of KIRs rec-
ognizing group 1 HLA-C alleles (KIR2DL2), group 2 HLA-C
alleles (KIR2DL1), and HLA-Bw4 alleles (KIR3DL1) was deter-
mined with mAb EB6, GL183, and Z27, respectively (29) (pro-
vided by L. Moretta, University of Genova, Italy). Anti-HLA
class I mAb and ME1 and B27M2 anti–HLA-B27 mAb were ob-
tained from American Type Culture Collection (ATCC).
 
Preparation of NK Cells and NK Cell Clones.
 
NK cell–enriched
preparations were obtained from PBMC by negative immuno-
magnetic selection (Dynal) of T cells, B cells, and monocytes with
anti-CD3, -CD20, and -CD14 mAb (Immunotech) and were
cultured with 100 U/ml rIL-2 for 4–6 d before cell-killing assays.
For NK cell cloning, PBMC depleted of T cells by negative im-
munomagnetic selection with anti-CD3 mAb (OKT3; obtained
from ATCC) were plated at the concentration of 10 cells/well in
96-well microtiter plates, activated with PHA, and cultured with
IL-2 and irradiated feeder cells as described elsewhere (30). Bulk-
cultured and -cloned NK cells were used as effectors in standard
(30) 
 
51
 
Cr-release cytotoxicity assays using autologous gene–trans-
ferred T cells as targets. E/T ratio was 10:1.
 
Analysis of NK Clone Allospecificity.
 
Standard 
 
51
 
Cr-release cyto-
toxicity assays against cell lines transfected with class I genes (pro-
vided by L. Moretta) determined NK clone allospecificity. Specific-
 
ity for group 1 (Cw4-related) and group 2 (Cw3-related) HLA-C
allotypes was analyzed using the HLA class I–negative cell line
721.221 and 721.221 cells transfected with Cw*0401 or Cw*0302
genes, respectively (31). Specificity for HLA-Bw4 allotypes (such
as HLA-B27) was analyzed using untransfected C1R cells and
C1R cells transfected with B*2705 gene (29). Specificity for the
nonclassical MHC class Ib molecule HLA-E was analyzed using
C1R cells expressing HLA-B7 (29) (cell surface expression of
HLA-E is regulated by the binding of peptides derived from the
signal sequence of some other MHC class I molecules, such as
HLA-B7) (3). E/T ratio was 10:1. Results are presented as per-
cent inhibition compared with lysis of the untransfected 721.221 or
C1R cells. Clones lysed the untransfected cells at levels exceeding
60%, whereas lysis of autologous cells (PHA lymphoblasts) never
exceeded 5%. NK clones were considered specific for a given al-
lotype when cytotoxicity was 
 
,
 
50% of control lysis obtained
against untransfected cells.
 
Vector Preparation; Transfer and Selection of Transduced Cells.
 
The
PA317 amphotropic packaging cell line was transfected with the
pLXSN retroviral plasmid (32), G418-selected, and subcloned. A
high retroviral titer clone was used to infect cells. To construct a
retroviral vector unable to produce the neo protein, the SV40
 
neo
 
transcriptional unit was deleted from the LXSN plasmid by
BamH1–Nae1 restriction digestion, Klenow blunting, and religa-
tion. The modified plasmid was transiently transfected in Phoenix
amphotropic packaging cells (33) to produce retroviral particles.
To construct a retroviral vector carrying a 
 
neo
 
 gene encoding a
mutated protein that cannot produce potentially nonprotective
peptides, the 209 cystine TGT codon of the 
 
neo
 
 gene was mu-
tated to TGA to truncate the reading frame. The LXSN plasmid
was consequently used as a template in a PCR reaction with the
following mutagenizing oligonucleotides: 5
 
9
 
-TGCAAAAAGC-
TTGGGCTGCAGGTC, 3
 
9
 
-CCCAGCCGGCCTCAGTCGAT-
GAATC. The PCR product was cloned and replaced in the
original LXSN plasmid at the Hind III–NgoIV fragment. The fi-
nal plasmid was sequenced to ensure that the open reading frame
of the 
 
neo
 
 gene was maintained throughout the cDNA to the
new stop codon. The plasmid was used to transiently transfect
Phoenix cells and produce retroviral particles. PHA-activated,
48-h IL-2–cultured T cells (PBMC forming rosettes with SRBC)
were infected by repeated cycles of centrifugation in the presence
of viral supernatants. For cloning, T cells were plated at the con-
centration of 0.5 cells/well in 96-well microtiter plates and cul-
tured with 100 U/ml IL-2 and irradiated feeder cells. The gene-
transferred T cell clones were identified by PCR on DNA.
 
PCR. 
 
For PCR on DNA, 10
 
5
 
 lymphocytes were lysed in
100 ml of a buffer containing 10 mM Tris/HCl, 50 mM KCl,
2.5 mM MgCl2, 0.1% gelatin, 0.45% NP40, 0.45% Tween 20,
and 100 mg/ml proteinase K. 10 ml of extract was used for a PCR
reaction with the following 
 
c
 
 region primers: 5
 
9
 
-TGGTTCTG-
GTAGGAGACGAG, 3
 
9
 
-GCTTCCCAGGTCACGATGTA. Re-
verse transcriptase (RT)-PCR was performed with published 
 
neo
 
primers (34).
 
Peptide Pulsing of RMA–S-B27 Cells.
 
Peptides were synthe-
sized by solid-phase method on an automated multiple peptide
synthesizer (AMS 422; Aimed) using F-moc chemistry (35). Pu-
rity was confirmed by reverse-phase HPLC. TAP2-deficient
RMA-S cells transfected with the human 
 
b
 
2
 
m alone (referred to
in this report as RMA-S) or in combination with the HLA-
B*2705 class I gene (RMA–S–B27) were cultured for 24 h at
26
 
8
 
C (8). Peptides were added in two separate doses: 100 
 
m
 
M at
the onset of the experiment and an additional 100 
 
m
 
M 12 h later.
Peptide loading was documented by surface stabilization of HLA- 
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B27 as measured by immunofluorescence and flow cytometry.
RMA-S and RMA-S–B27 cells were 
 
51
 
Cr-labeled overnight
during the peptide pulsing. After labeling, cells were used as tar-
gets in standard cell-killing assays with KIR3DL1
 
1
 
 NK clones as
effectors (30). Some cytolytic assays were performed in the pres-
ence of Z27 anti-KIR3DL1 mAb (500 ng/ml) (29).
 
HLA Typing of Donors Used in This Study.
 
Donor 1: A2/A33,
B52/B35, Cw4; donor 2: A2/A11, B51/B27, Cw2; donor 3:
A2/A28, B44/B18, Cw5/Cw7; donor 4: A11/A28, B8/B35,
Cw4/Cw7.
 
Results and Discussion
 
LXSN Infection Confers Susceptibility to Lysis by Autologous
NK Cells.
 
Peripheral blood T lymphocytes were infected
with LXSN, and the transduced cells were selected in G418.
The selected cells as well as nontransduced control cells
were used as targets in cytotoxicity assays with autologous
IL-2–cultured NK cells as effectors. Transfer of LXSN con-
ferred susceptibility to lysis by autologous NK cells in three
consecutive, independent experiments (Fig. 1 A).
Immunofluorescence analysis of MHC class I expression
showed that killing was not the consequence of a downreg-
ulation of MHC class I molecules at the surface of the trans-
duced cells (not shown).
 
The Selectable Marker Gene, neo, Is Responsible for NK Cell
Lysis of Autologous LXSN-infected Cells.
 
The next step was
to identify whether expression of the heterologous select-
able marker gene, 
 
neo
 
, or the defective retroviral mRNA
itself (through translation of short open reading frames) was
responsible for susceptibility of LXSN-infected cells to ly-
sis. To this end, we measured NK killing of autologous T
lymphocytes transduced with the same retroviral vector
Figure 1. The antibiotic resistance gene neo within the retroviral vector LXSN makes LXSN-infected cells susceptible to autologous NK cell lysis. (A)
NK cell cytotoxicity against autologous T cells infected with LXSN (E/T ratio, 10:1). LXSN infection conferred susceptibility to lysis by autologous NK
cells. (B) NK cell lysis is not activated by autologous T cells infected with the same retroviral vector that does not contain the neo cDNA. Left panels,
PCR on DNA identified neo-positive, empty vector–positive, and nontransduced T cell clones used as targets for autologous NK cell killing (neo expres-
sion was confirmed by RT-PCR). Right panel, NK cell cytotoxicity assay on PCR-selected clones (E/T ratio, 10:1). All clones infected with the LXSN
vector carrying neo were lysed by autologous NK cells. All clones transduced with the empty vector and all nontransduced clones were resistant to lysis.
Figure 2. NK cell lysis of autologous neo gene–expressing cells is clonally distributed. It is a property only of NK clones bearing KIR3DL1 and exhib-
iting specificity for MHC class I alleles of the Bw4 group. (A) NK clones from four random donors (see Materials and Methods for HLA typing) were
evaluated for their lytic ability against autologous cells expressing the neo gene (E/T ratio, 10:1). Some clones from donors 1, 2, and 3 lysed the autolo-
gous neo gene–expressing targets. No clone from donor 4 lysed the target. (B) KIR expression and MHC specificity of lytic and nonlytic NK clones. For
analysis of MHC specificity, clones were used as effectors in cell-killing assays against cell lines transfected with the indicated class I allotypes. The results
are presented as percent inhibition compared with lysis of the untransfected cells; “autol.” indicates inhibition of lysis mediated by autologous PHA lym-
phoblasts. All clones from donors 1, 2, and 3 that lysed the autologous neo gene–expressing targets, but none of the nonlytic clones, exhibited Bw4 spec-
ificity and expressed the Bw4 receptor KIR3DL1. An example of data from experiments with one lytic and one nonlytic clone from these three donors
is shown (see Table I for a summary of data from all clones of donors 1, 2, and 3). 
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that did not contain the 
 
neo
 
 cDNA. T cells underwent the
gene transfer procedure and were cloned by limiting dilu-
tion. Cells infected with LXSN were also cloned by limiting
dilution without antibiotic selection. PCR on DNA iden-
tified 
 
neo
 
-positive, “empty” vector–positive, and nontrans-
duced control targets for autologous NK cell–mediated
killing (Fig. 2 B). 
 
neo
 
 expression was confirmed by RT-
PCR. Remarkably, all of the 
 
neo
 
-transduced clones and none
of the empty vector–transduced clones (and none of the non-
infected control clones) were killed by autologous NK cells.
Therefore, within the LXSN retroviral vector, the 
 
neo
 
 gene
was responsible for conferring susceptibility to NK lysis.
 
Lysis of neo-Expressing Cells Is Mediated by NK Clones
Bearing KIR3DL1 and Exhibiting Specificity for HLA-Bw4.
 
The 
 
neo
 
 cDNA might include sequences that could be trans-
lated into heterologous peptides, replacing the autologous
peptides at given MHC class I alleles, so that NK cells with
the appropriate MHC receptors recognize the neo peptide–
loaded alleles. To test this hypothesis, several NK clones
were obtained from four random donors and used for cyto-
toxicity experiments with autologous LXSN-infected cells
as targets. Interestingly, as illustrated in Fig. 2 A, some NK
clones from donors 1, 2, and 3, but not from donor 4, killed
the 
 
neo
 
 gene–expressing autologous targets. The three well-
defined KIR specificities (1, 2) were presumably present in
these donors, because donor 1 and donor 2 expressed group
1 HLA-C and Bw4 HLA-B alleles; donor 3 expressed group
1 HLA-C, group 2 HLA-C, and Bw4 HLA-B alleles; donor
4 expressed group 1 and group 2 HLA-C but not Bw4 al-
leles (this donor, in contrast to the other donors, was ho-
mozygous for HLA-B alleles of the Bw6 group, which is
not recognized by KIR) (see Materials and Methods for
HLA typing). Clones were, therefore, analyzed for these
KIR specificities by the use of target cells expressing the
HLA-Bw4 allele B27, the group 2 HLA-C allele Cw3, and
the group 1 HLA-C allele Cw4 and for expression of the
corresponding KIR (Fig. 2 B and Table I). Control targets,
not recognized by KIRs, were cells expressing B7 (the
 
Table I.
 
MHC Specificities and KIR Expression of Clones from Donors 1, 2, and 3
 
Clone
No.
MHC specificity
 
*
 
non-KIR
ligand
 
§
 
KIR ligands KIR
 
‡
 
HLA-B27
(Bw4
HLA-B)
HLA-Cw3
(group 2
HLA-C)
HLA-Cw4
(group 1
HLA-C)
KIR3DL1
(BW4
HLA-B)
KIR2DL1
(group 2
HLA-C)
KIR2DL2
(group 1
HLA-C) HLA-B7
NK clones with lytic activity against autologous cells expressing the 
 
neo
 
 gene
1.2
 
21 2 212 2
 
1.4
 
21 1 211 2
 
2.2
 
21 1 111 1
 
2.3
 
11 1 211 2
 
2.4
 
21 2 112 1
 
2.5
 
11 2 212 2
 
3.1
 
21 1 211 2
 
3.2
 
21 2 212 2
 
3.4
 
21 1 212 2
 
NK clones without lytic activity against autologous cells expressing the 
 
neo
 
 gene
1.1
 
12 1 221 2
 
1.3
 
12 2 222 2
 
2.1
 
22 1 121 1
 
2.6
 
22 2 122 1
 
2.7
 
22 1 221 2
 
2.8
 
12 1 121 1
 
3.3
 
22 1 221 2
 
3.5
 
22 1 121 1
 
*
 
1
 
 indicates allotype specificity, i.e., that NK lysis was inhibited to 
 
.
 
50% of control lysis by a target expressing the indicated allele (the correspond-
ing allele group is indicated in parentheses). 
 
2
 
 denotes lack of allele specificity, i.e., that lysis was unaffected by that target.
 
‡
 
1
 
 and 
 
2
 
 denote positivity or negativity for expression of KIR (the allele group recognized by each KIR is indicated in brackets).
 
§This HLA-B allele allows expression of the nonclassical MHC class Ib molecule HLA-E, which is not recognized by KIR (reference 3).1859 Liberatore et al.
binding of signal sequence peptides from certain class I al-
leles, such as B7, regulates the expression of HLA-E, a non-
classical MHC class Ib molecule recognized by CD94-
NKG2A) (3). All clones from donors 1, 2, and 3 that lysed
the neo-expressing autologous targets, but none of their
nonlytic clones, exhibited Bw4 specificity and expressed
KIR3DL1, a Bw4 receptor. Fig. 2 B illustrates data ob-
tained from one lytic and one nonlytic clone, and Table I
summarizes data from all clones of donors 1, 2, and 3.
These three donors expressed alleles of the Bw4 group. In
contrast, donor 4, whose LXSN-infected cells were resis-
tant to autologous NK lysis, did not express Bw4 alleles.
Thus, without exception, Bw4 specificity and the Bw4 re-
ceptor KIR3DL1 were the distinctive features of NK
clones triggered to lyse genetically modified autologous tar-
gets. Moreover, and again without exception, lack of Bw4
specificity and failure to express KIR3DL1 defined clones
that did not recognize the genetically modified autologous
targets. As expected, several clones coexpressed multiple
specificities and the corresponding KIRs. It was therefore
remarkable that, in spite of the fact that a number of speci-
ficities might be involved, expression of the Bw4 receptor
KIR3DL1 appeared to be both necessary and sufficient for
recognition of the autologous gene-modified cells. Im-
munofluorescence analysis of HLA-B27 on the LXSN-
infected cells from donor 2 revealed that susceptibility to
lysis was not a consequence of selective downregulation of
Bw4 molecules at the surface of the transduced cells (data
not shown).
The coexpression of other KIRs besides KIR3DL1 by
lytic clones suggests that neo gene expression might also
lead to the production of peptides interfering with MHC
recognition of other receptors. However, the pivotal role
of KIR3DL1 in detecting expression of the neo gene is em-
phasized by the presence of one neo peptide with anchor res-
idues for Cw4 and a residue at position 8 that prevents recog-
nition of HLA-Cw4 by KIR2DL2 (i.e., QYDDAVYFL)
(11). As shown in Table I, clones expressing KIR2DL2 did
not kill the gene-transferred cells unless they coexpressed
KIR3DL1.
Neo Peptides Prevent KIR3DL1 Recognition of HLA-Bw4
Alleles. Recognition of the Bw4 allele HLA-B27 by
KIR3DL1 is the most extensively studied model of pep-
tide-specific recognition of MHC class I by NK cells (8–
10). A comparison of the amino acid sequence of the neo
protein with sequences of peptides reported to block rec-
ognition of HLA-B27 by KIR3DL1 (Table II) showed that
several nonamers within the neo protein possess (i) anchor
residues at positions 2 and 9 that allow binding to HLA-
B27 (36) and (ii) residues at positions 7 and/or 8 that are
known to prevent KIR3DL1-mediated recognition of HLA-
B27 (8–10). In addition, other P7 and/or P8 residues that
prevent recognition of HLA-B27 were present within neo
peptides anchoring to Bw4 alleles of the other donors (Ta-
ble II).
We therefore asked whether neo peptides actually bind
Bw4 alleles and if this complex specifically affects interac-
tion with KIR3DL1. To this end, we synthesized one of
the HLA-B27–binding neo peptides shown in Table II,
GRLGVADRY, and the analogue peptide GRLGVAIHY,
in which aspartic acid and arginine at positions 7 and 8 had
been replaced by isoleucine and histidine, respectively. As
isoleucine and histidine at positions 7 and 8 are critical for
the interaction between HLA-B27 and KIR3DL1 (8–10),
the latter peptide was expected to be a protective version
of the original neo peptide. Peptides were loaded onto
HLA-B27 molecules of RMA-S cells, as indicated by the
surface stabilization of HLA-B27 molecules shown in Fig.
3 A. Peptide-pulsed RMA-S–B27 and control RMA-S
cells were used as targets for lysis by three randomly chosen
KIR3DL11 (Bw4-specific) NK clones (Fig. 3 B). Binding
of the neo peptide was unable to protect RMA-S–B27 cells
from NK lysis. In contrast, the analogue peptide conferred
protection from lysis. Protection was mediated by HLA-
B27 on target cells because no protection was conferred to
control RMA-S cells and by KIR3DL1 on the NK clones
Table II. Neo Protein Peptides with Potential to Interfere with NK Cell Recognition of the Bw4 Alleles of Donors 1, 2, and 3
Published
HLA-B27 RRISGVDRY ARFGIRAK TRYPILAGH RRYQKSTEL RRLPIFSRL
Neo protein
HLA-B27 GRLGVADRY QRIAFYRLL ARTRMEAGL
(donor 2) HRIERARTR
Neo protein
HLA-B52
(donor 1) LQDEAARLS EQDGLHAGS DQDDLDEEL GQDLLSSHL
Neo protein
HLA-B44
(donor 3) VENGRFSGF VENGRFSGF
Underlined residues indicate the amino acid substitutions along endogenous peptides that prevent NK cell recognition of HLA-B27 (references 8–10)
and the identical residues in neo peptides that bind to Bw4 alleles of donors 1, 2, and 3.1860 NK Cell Lysis of Gene Therapy–modified Autologous Cells
because it was abrogated by the addition of anti-KIR3DL1
mAb. Similar results were obtained with the other HLA-
B27–binding neo peptides shown in Table II. Therefore,
exogenously loaded neo peptides prevent recognition of
HLA-B27 by KIR3DL1.
To document whether the endogenous production of
these neo peptides is indeed capable of triggering autolo-
gous NK lysis, a stop codon preventing translation of the
last 56/265 amino acids of the protein was created in the
neo cDNA (Fig. 4 A). The resulting truncated neo protein
does not contain two of the four HLA-B27–binding, non-
protective peptides shown in Table II and used for the ex-
periments in Fig. 3 (GRLGVADRY and QRIAFYRLL).
T lymphocytes from an HLA-B271 donor were transduced
with the truncated neo protein–expressing gene and used as
targets for autologous NK lysis by KIR3DL11 clones (Fig.
4 B). This deletion of z1/5 of the protein reduced lysis by
over 60%. Importantly, the deleted fragment did not con-
tain other HLA-B27–binding peptides with P7 and/or P8
residues that could have triggered autologous NK lysis.
Therefore, the reduction of NK-mediated lysis of autolo-
gous T lymphocytes infected with the mutated vector must
be attributed to the deletion of the two nonprotective pep-
tides.
Taken together, the experiments in Figs. 3 and 4 indi-
cate that neo gene expression by LXSN-infected cells from
HLA-B271 individuals can generate peptides that prevent
KIR3DL1-mediated recognition of HLA-B27 and trigger
autologous NK lysis.
The fact that 721.221 or C1R cells commonly trans-
fected with class I genes for NK recognition employ neo se-
lection may seem perplexing and opens the question as to
why these cells, when they express Bw4 alleles, are not
rendered susceptible to lysis by neo peptides. Our data
show that the susceptibility to lysis conferred by the neo
gene is limited. On the other hand, the degree of protec-
tion conferred to 721.221 or C1R cells by class I transfec-
tion seldom reaches the 100% level of unmanipulated au-
tologous cells, even when NK clones with single class I
allele specificity are used. It is therefore plausible that the
neo gene also partially antagonizes the protective effect of
Bw4 allele expression in 721.221 or C1R cells.
The fact that clones with specificity for Bw4 allotypes
were responsible for killing autologous LXSN-infected
cells implies that it should be possible to predict that HLA-
Bw41 individuals may possess an NK cell repertoire with
potential to clear gene therapy–modified cells. Individuals
(like donor 4) homozygous for the reciprocal group of
HLA-B allotypes, Bw6, should tolerate the engineered
cells. Assessment of the impact of the present findings on
survival of gene-transferred cells will require monitoring of
gene expression at serial times after the reintroduction of
engineered cells in vivo. We had the opportunity to evalu-
ate two patients with adenosine deaminase deficiency un-
dergoing adenosine deaminase gene therapy with the
LXSN vector (carrying neo) (26). One patient expressed al-
leles of the Bw4 and Bw6 groups, and the other was ho-
Figure 3. Neo peptides prevent recognition of
HLA-B27 by KIR3DL1. (A) The neo peptide
GRLGVADRY (shown in Table II) and the ana-
logue-protective peptide GRLGVAIHY (in which
aspartic acid and arginine at positions 7 and 8 had
been replaced by isoleucine and histidine) were
loaded onto HLA-B27 molecules of TAP-deficient
RMA-S–B27 cells. Surface stabilization of HLA-
B27 in the absence (hatched bars) or presence
(open bar) of neo or analogue peptide (filled bar).
(B) Binding of the neo peptide was unable to pro-
tect RMA-S–B27 cells from lysis by three ran-
domly selected KIR3DL11 NK clones (open bars).
The analogue peptide conferred protection from
lysis (filled bars). Protection required expression of
HLA-B27 on target cells because it was not con-
ferred to control RMA-S cells, and it was mediated
by KIR3DL1 on NK clones because it was abro-
gated by the addition of anti-KIR3DL1 mAb
(hatched bars).
Figure 4. Neo gene mutations that stop nonprotective peptide expres-
sion reduce autologous NK killing. (A) Neo protein amino acid se-
quence. The large box shows the truncated neo protein obtained by in-
serting a stop codon into the neo cDNA. The small boxes indicate the
potentially nonprotective HLA-B27–binding peptides (shown in Table II
and used for the experiments in Fig. 3). (B) KIR3DL11 NK clone killing
of autologous HLA-B271 cells transduced with neo (checked bars) and
with the mutated neo gene (filled bars).1861 Liberatore et al.
mozygous for Bw6 alleles. Both patients had undergone
gene therapy simultaneously 4 mo before our assessment.
The HLA-Bw41 patient, compared with the HLA-Bw61
patient, exhibited 100-fold lower levels of the transduced
gene.
Finally, our observations, by demonstrating that NK cells
can selectively detect the expression of heterologous genes,
provide a general model of the NK cell–mediated control
of viral infections.
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